Interim report
Page 1
October 31, 2025 National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: LALPATHLAB BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539524 Sub: Outcome of Board Meeting held on October 31, 2025 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, Please take note that the Board of Directors in their meeting held today i.e. October 31, 2025, inter-alia considered and approved the following(s): Financial Results 1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2025. A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations is attached herewith as Annexure-A. Interim Dividend 2. Declaration of 2nd Interim Dividend of INR 7/- per equity share (@ 70% on a face value of INR 10/- each) for the financial year 2025-26. The record date for the purpose of payment of Interim Dividend shall be November 7, 2025. The 2nd Interim Dividend will be dispatched/ credited within 30 days of its declaration. Bonus Issue 3. Issuance of bonus equity shares in the proportion of 1:1 i.e. 1 (One) fully paid-up equity share of face value of INR 10/- each for every 1 (One) fully paid -up equity share of face value of INR 10/- each held by the Members of the Company as on the Record Date, subject to Members, statutory and regulatory approvals, as applicable. The record date for determining the entitlement of the Members of the Company to receive bonus equity shares will be announced in due course. The details as required in accordance with SEBI Master Circular No. SEBl/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure-B.
Page 2
Alteration in Memorandum of Association (MOA) to increase authorized share capital 4. Alteration to the Capital Clause (Clause V) of the Memorandum of Association (MOA) of the Company to increase the authorized share capital from INR 1,07,96,00,000/- (Rupees One Hundred Seven Crore Ninety Six Lakh Only) to INR 2,00,00,00,000/- (Rupees Two Hundred Crore Only), subject to the approval of the Members of the Company. Amended Clause V of MOA: V. The Authorized Share Capital of the Company is INR 2,00,00,00,000 (Rupees Two Hundred Crores Only) divided into 20,00,00,000 (Twenty Crores) Equity Shares of INR 10/- (Rupee Ten Only) each. The Amended MOA will be submitted after the approval by the Members of the Company. Employee Stock Option Scheme 5. Introduction of “Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025” (“RSU 2025”) with the Options/ Shares reserve allocated out of reduction of Options/ Shares reserve from existing “Dr. Lal PathLabs Employee Stock Option Plan 2022” (“ESOP 2022”), subject to the approval of the Members of the Company. The details as required in accordance with SEBI Master Circular No. SEBl/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure-C. The Board Meeting commenced at 10:30 A.M. (IST) and concluded at 01:55 P.M. (IST). We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above
Page 3
• I • I a..t.rtd Aaaunblnts ocr tdln110 owtrO DlF(yt60yComp Ol1Gty~II Gunlsfam-1 D 002 HlfY'rta. lndl, li •91124 679 2000 Fu: +91 124 679 2012 I DEPE DENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOUDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF Dr .. LAL PATHLABS U'11 I ED 1.. We have reviewed the aa:ompanying Stata,,ent of Unaudited Consolidated Financial Results of Dr. Lal PathLabs Umited rthe Parent1 and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and six months ended September 30, 2025 ( the Statem,nt'), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Ustlng Obr1gatfons and Disclosure Requirements) Regufatrons, 2015, as amended (•the UstJng R,gulatlons1, 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prtpared in accordance with the recognition and measurement principles lald down In the Indian Accounting Standard 34 "Interim Ananclal Reporting" (•Jnd AS 341, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules lssu,d thereunder and other accounting principles generally accepted In India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility Is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement In accordance with the Standard on Review Engagements (SRE) 2410 "'Review of Interim Flnandaf Information Performed by the Jndep ndent Auditor of the Entity•, Issued by the Institute of Chartered Accountants or India (ICAI). A review of Interim financial Information consists of making Inquiries, primarily of Parent's pcrsonn I responsible for flnanclal and accounting matters, and applying analytical and other review procedures. A review ts substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be ldentJfied In an audit. Accordingly, we do not express an audit op,nton. 4. The Statement lndudes the results of the followfng entitles: e) Dr. Lal Pathlabs Limited, the Parent company b) Paliwal Diagnostics Private lJmlted, a subslr4iary company c) Dr. Lal Pathlabs Nepal Private Limited, a subsidiary company d) Or. Lal Pathlabs Bangladesh Private Limited, a subsidiary company e) Dr. Lal Ventures Private Limited, a subsidiary company f) Pathlabs Unifiers Private Limited, a subsidiary company g) Or. Lal Pathlabs Kenya Private Limited, a subsidiary company (dissolved vide date of publication of gazette notification w.e.f. 13 September, 2024) h) Suburban OiagnostJcs (India) Private Limited, a subsidiary company (voluntary liquidated on 11 February, 2025 with distnbution of business undertaking to the Parent Company on a going concern basis) i) Centrapath Labs Private Limited, a step-down subsidiary company J) APRL Pathlabs Private Limited, a step-down subsidiary company k) Chanre Laboratory Private Limited, a step-down subsidiary company 5kln q, "' ...., d a, ..... -·- Ac -0 (IJ ~ .. • ,. ., Regd. Office: One Jntemational Center, Tower 3, 31st floor, SenapatJ Bapat Mara. Elphlnstone Road (West~ Mumbal-400 013, Maharashtra. India. Deloitte HaskJns & Sells llP Is registered with Umlted Uablllty haVlng LLP ldenUficatlon No: MB-8737 I I I J ' I ' I I ' ' -·----·•-- ...... Scanned with a, CamScannef Annexure - A
Page 4
• • Deloitte Haskins& lsLLP • 5. Based on our review conducted and procedures perforrr,ed as stated In paragraph 3 above noth ing has come to ou.r atten ·on that causes us to believe that the Statement, prepared Jn accordance with the recognition a d measurement principles latd down fn the aforesafd Indian Aa:ounting S andard and other accounting principles generally accepted In India, has not d"sclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disdosure Requirements) Regulations, 2015, as amended, including the manner in w tch it is to be disclosed, or that it contains any material misstatement. 6. The unaudited Consolidated Financial Results indude the unaudited interim financial results and other unaudited financial information of two subsidiary companies which have not been reviewed by their auditors and have been approved and furnished to us by the Management, whose tnterim financial results reflect total assets of Rupees 337 .56 Million as at September 30, 2025, total revenue of Rupees 55.82 Million and Rupees 107.25 Million for the quarter and six months ended September 30, 2025 respectively, total loss after tax of Rupees 2.25 Million and Rupees 2.97 Million for the quarter and six months ended September 30, 2025 respectively, and total comprehensive loss of Rupees 0.83 Million and Rupees 1.55 Million for the quarter and six months ended September 30, 2025, as considered in the Statement. Our conclusion on the Statement, in so far as it relates to the amounts and disdosures included in respect of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial Information certified by the Management. According to the Information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement in respect of matters stated In para 6 above ls not modified with respect to our reliance on the financial results certified by the Management. • Place: Kasauli Date: October 31, 2025 • For DELOI r IE HASKINS & SELLS LLP Chartered Accountants {Arm Registration No.: 117366W/W-100018) "~ins ~ 0 - Chart1r1d -..- -- Accountanta c,, • TANDON Partner Membership No: 95540) (UOIN: 25095540BMOXJS1479) • • • Scanned with I} CamScanner ··
Page 5
• • . - - - - - - ~ -- 9", Laf. UhlJrnlte• - Q'9t Lt elttlrL.JMtl\C181JU ~.L- ~I l~L~ •111.fT I , IS ii I.I• Ni 11.•-•· Mau D ■ N ............... I C p; : :at»Oflll:a IJIII fl 1,, ream I, IAI Tewa. ii.s•dlt, l•t1• N, l•r 11011 • IJJ NI, N•w•ils I - - . p ·, • ttl 114 NIIRI I ftae ♦ ti 124 41211411: • I Rat ••••-••••·---• I _di ae•t,e.,_u, ,..,. ... C 1.,C F 1cc , 18 us• '"' 1n 11-,, ...... ._ II .. -4 * Msnlllt •••• JI la,tsR"II ••• H2t - - (PHI lfl ....... •a,t ff •kl) - - - -I , .. .. I , ....... . , ........ C1up N fff J Yew .. C JPtftfllM'N-✓ .,.. .. • ta n,u, cu f,w If llF • ,1t1 a ~, ..... Nia I lt,BU ... ' ' .. ,,. -· '"' ... t , -, ~Lil ..._,,n11u111ts• JIM•~ ::IOU ' CINICII• Ill ■ S• • ■ f .,..,.21 ... , ... , .. , JI l1Jllll!nl• , •n • I 119 l ■ 21l.a11,w, ... , , •• ,.14 fflA i ' I -- - - - - ' c- ■, .... , - , .. 11stc" a •J ,-......... , ( .. rsa1 .... , (Vvl ·••> (URI s Illa 1) {Ulla•·••> (\Pts"1c1) (Urs "' ,, , .. , .... , ---- I In C I I I (I ) t! - - , .... ...... ,,_ _, _ca • 7,JOI l ,IOJ IJ,IZI Z4,l14 f'>Od• Ir C .. 241 Jtl Zll s2, 48 ,,. - - - T.._.h I 7,sM e.•n a.•i• ' 14,1.J,J u , ... u ..... - 2 I ; s •• (1) C..fl . r,_ C 1,411 1,2n 1,273 J,701 Z,Af7 .. ,,1, ___ a (b) ~ -•L;• . l.lll l.lll l,241 J.145 J,4N 4,124 ·- (c)A•o C .. 47 '° n azo UJ (1)- Dc xtae,,...., ••• , E Ill 0 II '°' l4t Jll 7Sl 100 l,4tt • <•>,_It an :1111 : cabi .Wdls,•ial ,, t• 1 1,G6l ,u 1]7 l,NS 1,774 J,417 I (f)ClJ • e: •· a uu J.241 1,127 2,SOJ Z,249 4,601 ' T--• , .... ..... . .... 4,tN , ..... .. , .. lt,HI l , ......... J.,IH ..... l,IJI J . .M7 J,JN e,147 - • T• $ • ll (I ) Ca1•C .. 471 450 414 ,n nz a.no {'J D s'.'t n,4 ll5l 41 21 Jt '2 IZ (ltS ) -- Tulal-.1; •• ••• 471 11J NS ... l,.JD . - - - ' .,,.,.._ ... ,,,.,,,a, l.JJJ 1,14• 1,>1■ 2.Nl :a.:a•• " ... ,u . • an ••a; • ••tu• Inc ■ - ,.,, ... , • .... 91111wllfl■IINl ■ :1 • ., .. jlii aflt - ... ... , ..... ,,.,. '"' If ls - 11 (12) (10) ' (12) ('") • 11 1 1 ■ll' s:• Ir -""' • 1ft • s1 ■1l'I Fil 1s h I •• lha:I .. Nt • J (2) J h ·• •111irs1 ta ;. aflt • 1w (I) J ll • ...,,.1N1...,-t111r!ld1 n,,t .. ► u.""" ... (1) 2 -lrctn'III --• _e.., •• CClfl ti,_ .. .,. IJI- 1111 2 • • • T_, •· • •1t1;: al tll l,a la111Mt/ (IJN) (I) II (9) (I) • (t) (H) ' T .... I ■,.., ., , 1t110 lir'I 1111111 (A+I) UJ7 l ,SJI .... 2.111 J.J77 4,na I ......... ,,r1,, ...... ,, .... Ow ... 1.t1MC1•t111 ,, l,JOI 1,124 1,292 Z,llO Z,156 .. ..,, ,. .. , ......... ___. 11 11 11 ll lO ·SI 1,112 a,:a.e l,He l,,NJ UN 4,922 . OU•• •m;: alaulll'J ■ IR:::1 m1/(1Ne) tw 1111 ,..,,, .... rt ...... o ..... ., flte C.-,,111 ,, I IS (t ) (I) I (t) (36) -~--- • • • - - - • •• ,., (I) • (t) (H) TCIM ••> al 1ratra 1,111•1 ,_ ... $111 11, 1111>11:t. ... la ... o ..... ., ... Cl 7"1111( 1,521 l ,JlS 1,214 2,IH Z.l47 4,13.5 ' ... CID • d!Jlt IMaJ_a 11 11 1, ' l2 lO Sl • 1.117 l,JJl l ,-30I 2,,111 1,377 ..... • ,1if .. ..-tv ..... Q:Ptil ('ace "..._ ., M 10 ,., lfl.,.) Ill 1-31 IH 131 836 13' t Ott.~J"' I , 20,Ml ,. ,, I , 10 femt"II ,- """9 (IIIM.) - ' . (P:_.. •--ol N 10 • "'-•) I , (MC .,-.,hrlliJN,.. ··•:rt•rs) .... " 11.0S IS.II 15.52 Jl.tJ 2■ .lO 51..41 ,c)jlulaf 11.01 ts.cs ., .... Jl.17 28.24 51.40 ' - • • • • I Scanned with : ~ CamSc anner ~
Page 6
Notes. Dr. Lal P thlabs Umlt d The bove consolidat d results were rev wed by the Audit Committee and approved by the Board of Directors n their respective meetJngs held on 31 Octot>e_r, 2025. The m ed revi w, as required under R gulatJon 33 of the SEBI (Ustfng Obr,gatfons and Dlsdosure Requirements) Regulations, 2015, has been comptettd by the Statutory Auditors for the quarter and six months ended September 30, 2025 and they have expressed an unmodified concluslon on the fo,~ d results . J . n, abov consoUd ted results repre.sent consolidated results of the Company and Its subsidiaries (together referred to as 'the Group'). ii . These financial results af the Group have been prepared In accordance with the recognition and measurement principles laid down ln the Accounting Standard 34 "Interim Financial Reporting• c·1nd AS 34•), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules Issued th~under and other accounting principles generally accepted In India. v. During the six months end d 30 September 2025, the Parent Company has Issued 183,775 equity shares of face value of INR 10 each , to •or. Lal Path labs Empk>ye Welfare Trust" under Employee Stock Opt on Plan, 2022 c•esoP Plan, 2022·). v. The Board of Directors of the Parent Company have approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at thei m etlng h Id on 31 October, 2025. • Th Board of Directors of the Parent Company had approved an Interim dividend of INR 6 per equity share (face value of INR 10 each) at their meetJng held on 31 lufy, 2025 which was paid on 14 August, 2025 The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. vi. The Hon'ble Allahabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT1 sanctioned the Scheme of Amalgamation ('Scheme ') between the subsidiaries Pallwal Medicare Private Umlted (PMPL) (Transferor Company) and Paliwal Diagnostics Private Umlted (PDPL) (Transferee Company) on 3 September, 2024. The appclnted date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, ssets, Interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamatfon had been accounted for under the 'pooling of Interests' method In accordance with Ind AS 103 "'Business ComblnatJons" and the assets, llabllltles and reserves of the Transferor Company had been ac~unted for at their book value, In the books of Transferee Company. - vii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited c•so1PL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provis ons of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary Uquldation of SDIPL On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertakJng of SDIPL to the Company, on a going concern basis. The above dlstributJon resulted In tnter-1111 recognition of long term service agreements In block of Intangible assets In tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised In statement of profit or loss for the quarter and year end d 31 March 2025. vlll. The Board of Director's of Parent company at their meeting held on 31 October, 2025 approved Issuance of bonus shares, In the proportion of 1: 1 l.e 1 {one) bonus equity share of INR 10 each for every 1 (one) fully paid-up equity share , subject to Shareholders approvals. tx. During the year ended 31 March 2025, Dr. Lal Pathlabs Kenya Private Umlted (Wholly Owned Subsidiary), a Company Incorporated In the Republic of Kenya, was dissolved and Its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024. x. As at 30 September,2025, the Parent company has the following subsidiaries: subsidiaries step-down subsJdJar1$s JV /Associate Company-Nil Paliwal Diagnostics Private Umited Centrapath Labs Private Limited Dr. Lal Pathl.abs Nepal Private Umlted APRL Pathlabs Private Umlted Or. Lal Pathlabs Bangladesh Private Limited Chanre Laboratory Private Or. Lal Ventures Private Limited Limited PathLabs Unifiers Private Limited xi. The Board of Directors, which has been Identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysts of the various performance Indicators of the Group as a single unit. Therefore there Is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies {Ind ian Accounting Standard) Rules, 2015. xii. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure·B for Consolidated Cash Flow Statement. PJace; Kasaulf Date: 31 October, 2025 on behalf of th oard of Directors of athuabs Umi.,_ • ~~~~ ) Brig. Dr. Arvlnd Lal Executive Chairman Scanned with ~ Cam Scanner -
Page 7
Dr. Lal 'lltllltat .... !111 .. c...- ... _. ....... Aaal 2S ( ( 1 • 2.9Sl 1 • .-- 1~2 1 57 re 166 35 332 334 S,'81 5, 1 2,209 2.5 11 ) 10 J 1)4 812 ( ) 1S8 97 tp . ) ?91 ) 115 39 Ti 14,HI U,5ll 2. (1) 502 361 ) I {J) ' 4,855 l,267 ( ) 1' 1,011 1 ~ ) 1,161 ~926 (w) ( ) 7,001 5,461 ( w) LM 11 11 (YI) 310 S04 (c) 261 224 T ~ lS 191 lJ 6JS Teul 21,512 27,lU -- 1. <•> Ill 136 (b) 23,040 20,191 MetetM of die co,... ■ nv ll,871 21,727 34) lll T..a~ 24,221 MS L (e) I (I) 9 1,026 (D) ( ) 29 ll (c) 21 19 T LOlt 1.011 C•) (I) 571 S41 ( )Trade,-y TOW dfflkrO 212 135 ; Md ToCAt thanm.oo 1,701 1 Sl Cc ♦ total l,IU LIii • ( ou ... r. 644 561 Cb) 411 352 (C) tu (Mt) 290 138 cf) a,,mC SOl 431 T CWNflt 4,3J2 4,025 r.- S • 71 S 10J T 29,512 27,lU Scanned with Ii) Cam Scanner
Page 8
• • ( ) fo ns lcha Ml fer( )/ '" ., •• u .... • • (I ) fn (I ) (JJ ) (I ) fn (I ) In • ,.,. /(dbCf I re) In o,eratfnt ltaltlNUu: L In paya I In nn nd •bll I ) In provllto I ) In t 1bl c.att ••• •tM from o,-■ ttOM Jnc:om Uk N.tcash Nd l,y o,....ttnt a.ctfvl&w (•) Cewt;: flow• fsOffl Inv • -cd"ltl•• Payfflt'ft for pure.ha of property, s,Cent •nd u Pmfflt Proc.Nds from diilODMI of property punt and u pment Payments fo, purd\a of other Int.ant R Income from Inv nt pro rty lm-atree2llVH cash outflow for lnv-•-•·nt In su Id rt P•y-ntc for purcha of nvestments In muw I funds f'roc:eeds from sale or nvestmenu In mutu I funds Ben depoltts placed wtth the b ks ~ depotks with banks ncashed Net cash (•••d) In lnvwallnt adiVRMl8 (II) CeP nows from flnandnt ectlvltlu Proeeeds from • erct of share options Interest pa Res,,yment of borrow ings ~yment of IUJW, ILllhl llltv Interest pa on 1se 11..,. llif'y Ol"'dend pad on equity lhares N ca•h (UN.-) In tlnandnt KtivltJu (c) N Iner•••• In ca.,. an4 cash ulv■ &ena (e+b+c) C. 1nd Gish equlvalcn at the beg nn ng of the ye.,. ca Ir and ce•tt ulval-.ts at ttN au of die rw C1mpon ■nu of cuh altld ca•h ecauh,■ lem. c.stionhand th sct)eduled benks : .. on Ql"eflt KCX>Unts , d~ With m.Wnty of than l months Ct aft and ceA equiv ems In Cb1h Plow Statament • • ' 2 • 2 9 S (335) (157) (17) (2) 138 95 751 7 13 6 1 4,347 (141) (150) (7) (26) (39) 119 28 3,240 (1,344) ◄ (48) 17 472 • (2,924) 1,493 (7,482) 5,932 in (1) • (180) (!J.4) (1,027) (1,765) 2,926 1,161 14 190 957 1,161 • 2.l 6 ()10) ( ) {17) (2) 118 120 700 11 13 (13) - 3,151 (95) (151) .. (3) (76) 2S8 21 (80) 15 J,749 683 J,o•• (106) 4 (SO) 17 442 (3) (J,225) 1,569 (9,050) 6,493 • S1 (23) (417) (166) (96) (1,053) (2,541) 3,609 1,068 15 167 886 1,061 Scanned with ~ CamScanner ~
Page 9
• Deloitte Chartered Accountants 7th Floor Bu dit1g 10 Tc:Mer B Haskins & Sells LLP DLF Cyb« Oty Complex Of..F City Phase II Gun,aram-122 002 Haryana, rncf.a Tet +91124 679 2000 Fax: •91 124 679 2012 INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF Dr. LAL PATHLABS UMITED 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Dr. Lal Path labs Limited c•the Company"), for the quarter and six months ended September 30, 2025 ("the Statementj, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which Is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared In accordance wlth the recognition and measurement prlndpres laid down jn the Indian Accounting Standard 34 "'Interim Financial Reporting" ("Ind AS 34H), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules Issued thereunder and other accounting principles generally accepted In India and In compliance with Regulation 33 of the Ustlng RegulatJons. Our responslblllty ls to express a condusion on the Statement based on our review. 3. We conducted our review of the Statement In accordance with the Standard on Review Engagements (SRE) 2410 'Rev ew or Jnterim financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review or interim financial Information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying anatytJcal and other revtew procedures. A review Is substantJaUy less In scope than an audit conducted In accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be Identified In an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated In paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared In accordance with the recognition and measurement principles laid down In the aforesaid Indian Accounting Standard and other accounting principles generarty accepted In India, has not dlsclosed the information required to be disclosed in terms or Regulation 33 ot the SEBI (Listing Obligations and Disclosure Requirements) RegulatJons, 2015, as amended, induding the manner in which it Is to be disdosed, or that it contains any materfal misstatement. Place: Kasauli Date: October 31, 2025 For DELOI 11 e HASKINS & SELLS LLP Chartered Accountants (Firm Registration No.: 117366W/W-100018) skin_, .., C111rt•,.d - RASHIM TANDON - counte - Partner Membership No: 95540) (UDIN: 25095540BMOXJR1276) ~gd. Offlcr. One lntematlonll Center, Tower 3, 31st noor. Senapad Bapat MM&, Etphlnstone Road (Wnti Mumbal-400 013, Maharashtra , lndta. Deloitte Haskins & Sells UP Is r~glstered with Umlted Liability having LLP ldent1flcadon No: MB-8737 Scanned with li1 CamScanner-
Page 10
O en n " ., Cl) 3 ::l 1/l ltl n c. ., :l: :l ;:::.: ::, :::r ltl • ""t, ••••• .: - I' ' I I • - ' I I ' ' f ' I ' I ' I • I ' I ' ' - . Dr. Lal ... - -- ·· - ' - - ·- - ~- CDI : 1.1 ·~""- ,.-- - - ,, .,.,.,...... ____ -~- ... - '9 - u, - -- - . -- - -. 11-· - . - .. . -- -- . -- - -- - -- - - - - - - -122 l. Mawr:.--· ..-.. ~ ....... - s . -----.. ,, _ .. T -Ja, ._.._ ... , .. ., - -• ♦ ti 124 11 I Pa: +11124 .,2344tl; --- • . - .... - .. . . • - ..... r WWW -- . . ..., - . .. '- - - - - . - - --- - ·- - - ~. --- - .. ,JO~S • . - . -. -r flNR III ml - - - - - I r ~ - I J .. - - ' J _, y ta .9'a ,.......,_,. _ __ y deM ~. -~ r • --· - . JO . ' ~ - - - '°' ._,,.. .. ~ ,_ ·-.. , .. - -- - -- - _ .. ' •• JO I DH I o- . 2011 . . JO • - . . ,.,, .. I ' r•--. ..,_ . .._.._ - . .. , 2024 - - -~--, 2025 - . • , 2024 I - r . .. ( - v) ( nob! v) ' ' cu- -- - -, (U .. _:J (,.. ·- -, (~ .NJ r·. N) -~ · ·- -- I 1- . I (1) ~- --··--, I ~··- ·--- '· 6 6,407 6,309 , ll,403 12,0Sl : (b) w .. , I .. _..~ 221 2631 2-42 .t91 551 ' I ' T I : - - - 7,ll4 1,170 1,SSl lJ,114 , 12.ICM 2 • I • ' . I (a) t "'--· • • .:. , __ .. _,... co .. _.,;.;.,. 1,,.7 1,22, 1,204 2,S7J UJS (b) - • • - . ... -- - -.- 2,509 2,2 --■ - ...-- _ , ____ _,~--·1q ·-. 1,251 1,251 1,179 . (c) Fl--~- I 46 •s s 91 116 (d) ~ -.. · - -"I~ nd - . .. ' 661 "'• I .,.,.., .. ,. ·- 315 321 13' 713 . I ( )rmb> .. - i-----,.....-. , - - 1,7-42 '--· ...,._:,-, __ .. ,.~ ...--•-"11111•· I 1,0.tl 1 90J 920 l .~ (f) -·· - ---- ' ~- T -- - O' ~-~ 1,2 6 1,11 1066 2,]92 2,135 ' T ,.._.,. ... 5,271 .. ,, ... 4,711 10,222 9,275 l Pr9ftt ltefore ta_x 1,141 1,724 1,790 J,172 J,J2t ◄ T1 ·-. ·- I I (1) c~., . .,~ tlr ... , 409 461 158 179 (b) e-:,..,,.,d tax 42 22 41 "' 14 t'otaltuupw• 411 4JI - 502 t22 ltJ • 5 ,. -·•• for the p ■ rt•d (A) 1,417 1,2,, 1,21.1 2,750 2,4>& 6 ' Other COffl,r 11~--L-; lncome/(IHI) . - J m that wlll not be re~••• •1 -d to prof or los 11 (12) (11) 6 (ll) • m surem nt of the d ned b nt obf 1t1ons .. Jna,me tJix In relation m the mstnat not be (5) l l (2) 3 , -------1•~;: to proftt or loss . Total _ •• -, com,rehenllv• lncome/(lo11) (I) 1J (I) (I) 4 (10) ' 7 Total compr hen•v• Income (A ♦ I) 1,470 1,214 1,290 2,754 2,421 ' . I Pald~p equity MAI capital (fl v•J of INR 10 pe,r 838 JI • 136 Ill 836 _._ __ ) I _ _. ... 9 Other equity I I • L 10 Elml"9S per shl (JNR) ( •~v1 or INR l O per shire) (not 1nnu1 " ~ for qu,rt r,) . a. 17 .◄ 6 15.51 15.47 32.96 29.26 ' • 0 11 .... -~ 17.43 15.49 15 . 4◄ 32.89 29.20 ' I - - . . .. - •• lltate4) " .. ~ .,.., ... ,. .. ___ ,..r . . -JI Mardi, 2O2S (AudltN) 2J,516 1,115 24,131 4,552 4,5&4 215 1,342 J,351 4,]74 I 11,All ' 1,213 1,633 (]93) 1,240 4,17J (48) 12 I. (31) .. ,,J7 136 20,506 59.70 S9.61
Page 11
Dr. Lal ,attaLabs Umltad Not •: The above iuutts ~re ~lewed by lhe Audit Committee and approved by the Board of Diec.tors In their respective meetings held on 31 October, 2025. The lmbd review, as required under Regulation 33 rA the SEBJ (Ust:in9 Oblgltions and DiSdosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and stx nt0nths ended 30 Scpt~ber, 2025 and ti~ have expressed an unmodified condusfon on the aforesaid resuts. • These ftnandal results have been prepared In accow d•nce with the recognition and measurement prlndples lald down In the Indian Accounting Standard 34 •interim Financial ReportJna• C-lnd AS 341, pres.crtbed under 5ectJOn 133 of the Companies Act, 2013 read with relevant. rules Issued thereunder and other accounting pr'lfldples generaly accepted In India. Di. During the six months ended 30 Sept.ember 2025, the Company has Issued 183,nS equity shares of face value of INR 10 each , to ·0r. Lal Pathlabs Employee Wef, re Trust" under Employee Stock Option Plan, 2022 c•eso, Plan, 2022•). tv. The Board of Directors of the Company have approved second Interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 The Board of Directors of the Company have approved an Interim dtvldend of JNR 6 per equity share (face valoe of INR. 10 each) at their meeting held on 31 July, 2025 and this was paid on 14 August, 2025 The Board of Directors of the Company had proposed final dividend of INR. 6 per equtty share (face value of JNR 10 each) for the nnanclal year ended 31 March, 2025. The same was approved by the shareholders In the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025 v. The Board of the Company had eartter noted approval by the board of Suburban Diagnostics India Private Umited c•s01PL•), a wholly owned subsidiary of the Company for voluntary lquldatlon of SDIPL under the provisions of Insolvency and Bankruptcy coc:te, 2016, wherein the business undertaking of SOIPL was sought to be disbtbuted to the Company on a go~ concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary lquidatlon of SOIPL. On 18 March, 2025, the quldator of SDJPL based on the approved scheme has distributed the entlre business undertaking of SOIPL to the Company, on• going concem basis. The Slid dlstrtbutlon of business undertakJng has been accounted for using the poo Ing of tnterests method In accordance with Appendhc C of Ind AS 103 'Business combinations of entitles under common control'. Accordingly, the comparative financlal Information for the previous periods have been restated to give effect of the consummation of business undertaking from beginning of the period dlsdosed and al assets, labllities and reserves of SOJPL together with fntanglble assets - long a:,,,, service agreements and related deferred tax llabllity has been recognised In the Standalone Financial Statement. The above distribution resulted In Inter-a a recognition of long t1c1 a, servk:e agreements In block of Intangible assets In tax books of the Company at fair value on 18 March, 2025. Accordlngty, deferred tax credit of JNR •os mlNion has been recognised In statement of profit or loss for the quarter and year end 31 March, 2025. Accordingty, the results for the quarter and period ended JO September, 2025, have been restat~ to give effect of the Uquldatlon. vt. The Board of Director's at their meeting held on 31 October, 2025 approved Issuance of bonus shares, in the proportion of 1:1 1.e 1 (one) bonus equity share o INR 10 each for every 1 (one) fully paid-up equtty share, subject to Shareholders approvals. v . During the year ended 31 March 2025, Dr. Lal Pathlabs Kenya Private Umlted (Wholly Owned Subsidiary), a Company Incorporated in the Republic of Kenya, was dissolved and Its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024. viii . The Board of Directors of the Company, which has been ktentified as being the chief operating decision maker (COOM), evaluates the Company's performance, •llocates resources based on the analysis of the various performance Indicators of the Company as a single unit. Therefore there Is no reportable segment for the Company, In accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting St.andard) Rules, 2015. · ix. Rder Annexure A for Statement of Standalone Assets and Liabilities and Annexure B for Standalone cash Flow Statement Place: KasauU Date: 31 October, 2025 • don behalf of the Board of Directors of Dr. P11thlllb1 Umlted (Hony) Brig. Dr. Arvlnd Lal Executive Chairman • Scanned with • 'll CamScanner ~
Page 12
Ann xur A ,r---------- -...,;.- ______ __,;, __ ~---~~'!""'!"'"~~~-------------__,; .. ;.... ____ _ Dr. Lal PathLab Limit d ' ' i i : Sta m nt of Standalon • Au and II blnttu Partlculars -1. Non-current --- -!. ( ) Property, plant nd equlpm nt (b) Right-of•use assets (c) Cap' I work-In-progress (d) Inv t.m nt property ( ) Goodw (f) Ott, r In nglble ssets (g) Intang,b assets under developm nt (h) Anand I ssets (f) Inv stments (fl) 0th r nnanciat assets (f) Non-current tax assets (net) (j) Deferred tax ass ts (n t) (k) Other non-current assets Total non-current assets 2. Current ••- - (a) Inventones (b) Anandal ass ts (I) Inv tments (II) Trad recetv bles (iii) C sh and cash equlvatents (Iv) Bank balances other than (Ill) abov (v) Loans · (vi) Other finandal assets (c) 0th r current ssets Total current • ta Total assets ,1 Equity and Uablllti ;i 1. Equity i ' ' I I I : (a) Equity share capital (b) Other equity Total qulty 2. LI bllltl Non-current llabllltl s (a) Flnandal r ablttles (I) Li ase Uablllties Total non-current liabilities Current llabllitles {a) FJnandal liablllt es (I) Lease I abiUtles (H) Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises Subtotal ( ) Other financial llabllities (b) Provis ons (c) Current tax Dab lrtles (net) (d) Other current I ab litJes Total current llabf Htle1 Total Hablllti Total qulty and Uabllftl . (INR In mllllon except as ted) ' As t 30 S ptember, 2025 ' (Un udlted) ' 2,847 1,292 166 332 ,711 1,977 10 1,139 768 142 780 114 14,271 459 4,504 1,211 879 6,587 17 346 25S 14,258 21,536 838 22,572 23,410 . 947 947 546 206 1,647 1,853 622 393 290 475 4,179 5,12& 28,536 As t 31 M rch, 2025 (Audited) • . 1,900 1,307 35 334 4,711 2,261 - 1,139 797 69 845 39 13,437 323 3,017 1,054 2,666 5,009 10 480 214 12,773 26.210 836 20,506 21,342 983 983 526 131 1,800 1,931 ' • 547 336 138 407 3,885 4,858 26,210 Scanned with (i CamScanner -
Page 13
Dr. Lal PathLab1 Umlt d tandalone ca h Flow s t m nt Annuur I • (INR In mRIIOM ax pt •• led) rtlculars Clish newa from 0De:r11tln1 div t Pro for od A u.t111ents for : T expen 1n~ .. .-. 1nco ,A_ •• ,,..., lncom . rrom lnvesbtn:nt . property dend Income from • subs d ry company v In on fe or f Irv luatJon of Investments (at FVTPL) (Pro )/ Loss on dlspo I/ dlsatrd of property, plant and equlpm t (n ) & r-.c:oa1n.lsed In resc,e,ct of mploy share based compensation An nee cost OPN...,-f Uon end amort:1 tJon expen . Provision for lmpalrm nt of trade receivables nd advances B d debts and adv nces written off Remeasurem nt of th d nned be_neflt obflgatJon o ratJnt proffl before working capital and oth chang Chang In working capltal: AdJustm nt for (lncre•• )/deer a (lncrea e) In lnventortes (Jncreas ) In trade recetv bles (lnaease)/Dccrease tn loans (lncrea ) In oth r nn nd I assets (lncreas ) In other sset:s In QINl·ratlng •• eta: • AdJu•tm nt for lncreas /(d r •••> In operating llabllltlu: lncre se/(d crease) In de p yables Increase In other flnand I II blUttes Jncrease/(d~ase) In provisions lncrease/(decrea~e) In other II b lltlcs C.•h g n rated from operation ■ Incom tax paid . N t cash I n rated from operating actlvttl • (a) C.ah nowa from Inv sting acttvttl • P yments for purchase or property , plant and equipment Proc eds from disposal or property, plant and equipment Paymen for purch se of 0th r lntanglb le assets DlvJd nd rec Jved from a subsldl ry company Interest received Rental Income from Investment property Investment In subsldaries Payments ror purchas of lnvestm nts In mutual funds Proceeds from sale of lnvestm nts In mutu I funds Bank d posits placed with the b nks Bank deposits with banks encash d N t cash (uMd) In Inv •ting actlvltl•• (b) C.sh flows from financing actJvttJ • Proceeds from exercise or sh re op ons R paym nt of borrow ings R.J payment of I I llablllty Interest paid on lease Uablllty Interest paid o v dend paid on equity shares Net cash (u d) In financing actlvltl a (c) N t Increase/ decreas In ca•h and cash equlval nts (a+b+c) cash and c.sh equlva nts at the beginning of the year cash and cash equivalents at th nd of th• period/year Compon nta of cash and cash equlval nts C.sh on h nd Balance with scheduled banks: - on current ac.c.ounts • on cash credit accounts • d posits with maturtty of less than 3 months Total cash and cash equlval nts In C••h flow Stat m nt . Y ar to date ftgur for th current perfod ded 30 Septem r, 2025 2,750 922 (309) (17) - (145) (2) 138 91 713 9 13 6 4,119 (137) (179) (7) (26) (38) 106 26 56 115) 3,155 3,071 (1,327) 4 (4S) - 452 17 - (2,664) 1,322 (7,307) 5,776 (3,772) 1n - (176) (90) (1) (1,001) 1,091 (1,717) 2,666 171 13 132 - 734 171 V ar to date ftgur .1 for th• pravlous perfod ended 30 ptem r, 2024 (Unaudited) 2,436 893 (283) (17) (160) (88) (1) 118 116 661 ll 3,611 (90) (171) 3 (3) (72) 247 18 (83) 17 3,552 636 2,911 (106) 3 (49) 160 422 17 (3) (2,980) 1,359 (8,986) 6,081 4,012) S7 (417) (161) (93) (23) (999) 1,636 (2,102) 3,443 141 • 14 87 540 641 Scanned with (i CamScanne, -
Page 14
Annexure- B DETAILS AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/POD2/CIR/P/0155 DATED NOVEMBER 11, 2024: S. No. Particulars Details 1 Type of securities proposed to be issued Equity Shares of face value of INR 10/- each 2 Type of issuance Bonus Issue 3 Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately) 8,37,75,510 eq uity shares of face value of INR 10/- each amounting to INR 83,77,55,100/- 4 Whether bonus is out of free reserves created out of profits or share premium account The Bonus E quity Shares will be issued out of Securities Premium Account as per audited financial statement s of the Company for the financial year ended March 31, 2025. 5 Bonus ratio 1:1 i.e. 1 (One) fully paid -up equity share of face value of INR 10/ - each for every 1 (One) fully paid-up equity share of face value of INR 10/ - each held by the Members of the Company as on the record date. 6 Details of share capital - pre and post bonus issue Pre Bonus Issue Share Capital Authorised Capital – INR 1,07,96,00,000/- divided into 10,79, 60,000 equity shares of face value of INR 10/- each Issued, subscribed and paid -up capital – INR 83,77,55,100 divided into 8,37,75,510 equity shares of face value of INR 10/- each Post Bonus Issue Share Capital Authorised Capital – INR 2,00,00,00,000/- divided into 20,00,00,000 equity shares of face
Page 15
value of INR 10/- each Issued, subscribed and paid -up capital – INR 1,67,55,10,200/- divided into 16,75,51,020 equity shares of face value of INR 10/- each 7 Free reserves and/ or share premium required for implementing the bonus issue INR 83,77,55,100/- 8 Free reserves and/ or share premium available for capitalization and the date as on which such balance is available Securities Premium Account : INR 1,247.85 Million (as per audited financial statements of the Company for the financial year ended March 31, 2025) 9 Whether the aforesaid figures are Audited Yes, the figures considered are based on audited financial statements of the Company for the financial year ended March 31, 2025. 10 Estimated date by which such bonus shares would be credited/ dispatched Within two (2) months from the date of approval by the Board of Directors i.e., on or before December 30, 2025. Note: The total number of securities proposed to be issue is subject to change pursuant to the exercise of stock options by the Eligible Employees of the Company till the Record Date and consequently all the relevant details will get updated accordingly.
Page 16
Annexure- C DETAILS AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/POD2/CIR/P/0155 DATED NOVEMBER 11, 2024: S. No. Particulars Details 1 Brief details of options granted The RSU 2025 authorizes grant of the maximum 5,27,403 (Five Lakh Twenty Seven Thousand Four Hundred Three) employee stock options (“Options”), exercisable into not more than equal number of equity shares (“Shares”) of face value of INR 10/- each fully paid-up, subject to the approval of Members of the Company. 2 Whether the Scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable) Yes 3 Total number of shares covered by these Options The total number of Equity Shares to be issued/ allotted/ acquired/ transferred under the RSU 2025 shall be limited to 5,27,403 (Five Lakh Twenty Seven Thousand Four Hundred Three) equity shares of face value of INR 10/ - each fully paid -up of the Company. 4 Pricing Formula Exercise Price per Option shall be the face value of Equity Share prevailing as on date of grant of Option. 5 Options Vested Not Applicable 6 Time within which option may be Exercised Five (5) years from the date of respective vesting or such other shorter period as may be decided by the Nomination & Remuneration Committee from time to time. 7 Options exercised Not Applicable 8 Money realized by exercise of Not Applicable
Page 17
Options 9 The total number of Shares arising as a result of exercise of Option Not Applicable 10 Options lapsed Not Applicable 11 Variation in terms of Options Not Applicable 12 Brief details of significant terms The Options granted under the RSU 2025 would Vest not before one (01) year and not later than four (04) years from the date of grant of such Options. The Options not exercised within the Exercise Period shall lapse. 13 Subsequent changes or cancellation or exercise of such Options Not Applicable, to the extent of options to be granted under RSU 2025. Introduction of RSU 2025 with the Options/ Shares reserve allocated out of reduction of Options/ Shares reserve from existing ESOP 2022, subject to approval of the Members of the Company. 14 Diluted earnings per share by the Board of Directors. Not Applicable Note: In case of any corporate action(s) such as rights issues, bonus issues, merger and sale of division and others, a fair and reasonable adjustment will be made to the Options/ Shares.